These insights suggest that clinical strategies-such as recombinant IL-37 therapy, IL-35 modulators, or combination cytokine-targeted interventions-may restore immune homeostasis and improve outcomes in AP. The gene discussed is IL37; the disease is alkaline phosphatase measurement.